利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.033 秒)

    Determination of an analyte in a liquid medium
    1.
    发明授权
    Determination of an analyte in a liquid medium 失效
    液体介质中分析物的测定

    公开(公告)号：US06214205B1

    公开(公告)日：2001-04-10

    申请号：US09117256

    申请日：1998-12-15

    申请人： Itamar Willner ,  Eugenii Katz ,  Yael Cohen ,  Ron Blonder

    发明人： Itamar Willner ,  Eugenii Katz ,  Yael Cohen ,  Ron Blonder

    IPC分类号： G01N2726

    CPC分类号： C12Q1/003 ,  G01N33/5438

    摘要： Electrochemical determination of the presence, and optionally concentration of an analyte utilizes an electrode having immobilized thereon one member of a recognition pair, the recognition pair consisting of said analyte. In the presence of the analyte medium pair complexes, which are complexes between the analyte and the immobilized member are formed. The electrode forms part of an electrochemical system which includes also redox molecules comprising at least one first redox molecule and at least one second redox molecule, the former transferring electrons between the electrode and the latter. Upon formation of a pair complex the electron transfer is inhibited and the change in the electrical response then indicates the presence of said analyte in the medium.

    摘要翻译： 分析物的存在和任选地浓度的电化学测定使用其上固定有识别对的一个成员的电极，识别对由所述分析物组成。 在存在分析物的情况下，形成了分析物与固定化部件之间的复合物。 电极形成电化学系统的一部分，其还包括包含至少一个第一氧化还原分子和至少一个第二氧化还原分子的氧化还原分子，前者在电极和后者之间转移电子。 在形成一对复合物时，电子转移被抑制，并且电响应的变化然后指示所述分析物在介质中的存在。

    Determination of an analyte in a liquid medium
    2.
    发明授权
    Determination of an analyte in a liquid medium 失效
    液体介质中分析物的测定

    公开(公告)号：US06630309B2

    公开(公告)日：2003-10-07

    申请号：US08983570

    申请日：1998-06-04

    申请人： Itamar Willner ,  Shlomo Levi ,  Yael Cohen ,  Eugenii Katz ,  Arie Dagan

    发明人： Itamar Willner ,  Shlomo Levi ,  Yael Cohen ,  Eugenii Katz ,  Arie Dagan

    IPC分类号： G01N33553

    CPC分类号： G01N33/54373

    摘要： Binding between two members of a recognition pair, e.g. antigen-antibody is determined by utilizing a probe which includes a piezoelectric crystal with electrodes on two opposite faces of the crystal. The crystal carries one or more metal plates which may be the same or different than the electrodes, the metal plates having immobilized thereon a first member of a recognition pair. Binding of a second member of the recognition pair to the first member, or dissociation between the two members and release of the second member from the probe, causes a change of immobilized mass which results in a change to the probe's resonance frequency. The immobilized members may be immobilized on the surface of the metal plates by means of a linking group, having the following general formula (I): Z—R1—Q, wherein Z represents a sulphur-containing moiety which is capable of chemical association with, attachment to or chemisorption onto the metal, R1 represents a connecting group, Q is a functional group which is capable of forming a covalent bond with a moiety of said first member of the recognition pair.

    摘要翻译： 识别对的两个成员之间的绑定，例如 通过利用包含晶体的两个相对面上的电极的压电晶体的探针来测定抗原抗体。 晶体携带一个或多个可以与电极相同或不同的金属板，金属板固定有识别对的第一构件。 识别对的第二个成员与第一个成员的结合，或两个成员之间的解离和第二个成员从探针的释放导致固定的质量的变化，导致探针的共振频率的变化。 可以通过具有以下通式（I）的连接基团将固定化的构件固定在金属板的表面上：ZR 1 -Q，其中Z表示能够化学结合的含硫部分 与金属的附着或化学吸附，R 1表示连接基团，Q是能够与识别对的所述第一成员的部分形成共价键的官能团。

    Combined Treatment Utilizing VB-201
    8.
    发明申请
    Combined Treatment Utilizing VB-201 审中-公开
    使用VB-201的组合治疗

    公开(公告)号：US20120329758A1

    公开(公告)日：2012-12-27

    申请号：US13520713

    申请日：2011-01-05

    申请人： Yael Cohen ,  Niva Yacov ,  Eyal Breitbart

    发明人： Yael Cohen ,  Niva Yacov ,  Eyal Breitbart

    IPC分类号： A61K31/685 ,  A61K31/405 ,  A61K31/366 ,  A61K31/235 ,  A61K31/505 ,  A61P11/00 ,  A61P9/00 ,  A61P29/00 ,  A61P31/00 ,  A61P1/00 ,  A61P1/16 ,  A61P35/00 ,  A61K31/40 ,  C07F9/11

    CPC分类号： A61K31/685 ,  A61K31/198 ,  A61K31/366 ,  A61K31/40 ,  A61K31/505 ,  A61K31/683 ,  A61K38/02 ,  A61K45/06 ,  Y02A50/414

    摘要： Methods of treatment which utilize co-administration of the oxidized lipid VB-201 with an additional therapeutically active agent are described herein. Methods of treating a cardiovascular disease are described herein, comprising co-administration of VB-201 and a statin to a subject who is not fully responsive to the statin, as well as methods of treating an inflammatory disease or disorder, comprising co-administration of VB-201 and glatiramer acetate. A pharmaceutical composition comprising VB-201, identified for use in combination with glatiramer acetate, is also described herein. Methods of determining a therapeutically effective amount of VB-201 in a subject and of determining a therapeutically effective amount of VB-201 for co-administration with an additional therapeutically active agent are also described. Novel unit dosage forms of VB-201 and methods utilizing same are also disclosed.

    摘要翻译： 本文描述了利用氧化脂质VB-201与另外的治疗活性剂共同给药的治疗方法。 本文描述了治疗心血管疾病的方法，包括将VB-201和他汀类药物共同给予对他汀类药物不完全反应的受试者以及治疗炎性疾病或病症的方法，包括共同给予 VB-201和醋酸格拉默。 本文还描述了一种包含鉴定用于与醋酸格拉默的组合的VB-201的药物组合物。 还描述了确定受试者中治疗有效量的VB-201和确定治疗有效量的用于与另外的治疗活性剂共同施用的VB-201的方法。 还公开了VB-201的新型单位剂型及其利用方法。

    Fluvastatin sodium pharmaceutical compositions
    9.
    发明申请
    Fluvastatin sodium pharmaceutical compositions 审中-公开
    氟伐他汀钠药物组合物

    公开(公告)号：US20080033030A1

    公开(公告)日：2008-02-07

    申请号：US11710232

    申请日：2007-02-23

    申请人： Simona Capua ,  Yael Cohen ,  Ronit Yaffeh ,  Nava Shterman ,  Rina Zilberman

    发明人： Simona Capua ,  Yael Cohen ,  Ronit Yaffeh ,  Nava Shterman ,  Rina Zilberman

    IPC分类号： A61K31/404 ,  A61P3/06

    CPC分类号： A61K9/2054 ,  A61K9/2027 ,  A61K9/2866 ,  A61K31/405

    摘要： Various fluvastatin compositions and methods for preparing them are described. One example is a controlled release pharmaceutical composition comprising fluvastatin and at least one non-ionic hydrophilic polymer, wherein the composition is substantially free of hydroxypropyl methylcellulose. Another example is a stable pharmaceutical composition comprising fluvastatin, preferably, fluvastatin sodium wherein the composition is substantially free of an alkalizing stabilizing agent. Another example is a stable controlled release pharmaceutical formulation, comprising fluvastatin, preferably, fluvastatin sodium, that is stable with a water content greater than 3.5 percent by weight.

    摘要翻译： 描述各种氟伐他汀组合物及其制备方法。 一个实例是包含氟伐他汀和至少一种非离子亲水性聚合物的控释药物组合物，其中所述组合物基本上不含羟丙基甲基纤维素。 另一个实例是包含氟伐他汀，优选氟伐他汀钠的稳定的药物组合物，其中组合物基本上不含碱化稳定剂。 另一个实例是稳定的控释药物制剂，其包含氟伐他汀，优选氟伐他汀钠，其水含量大于3.5重量％是稳定的。